Saxenda is the brand name for liraglutide, a GLP-1 receptor agonist used with reduced-calorie diet and increased physical activity for chronic weight management in eligible adults and adolescents aged 12 years and older. The label describes appetite and calorie-intake regulation through GLP-1 receptor activity in the brain. U.S. labeling lists initial approval in 2010.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Novo Nordisk will reduce prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting January 2027. Meanwhile, WADA investigates potential Olympic ban on weight loss drugs, and Brazil's Anvisa reports 65 suspected deaths linked to GLP-1 medications.
Semaglutide and other GLP-1 receptor agonists demonstrate substantial weight loss effectiveness through appetite regulation and blood sugar control, with clinical studies showing average reductions of 14.9% to 20.9% body weight.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06217848 |
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study |
RECRUITING | EARLY_PHASE1 |
| NCT05111912 |
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity |
COMPLETED | PHASE2 |
| NCT03885297 |
3mg Liraglutide for Overweight or Obesity |
COMPLETED | |
| NCT03115424 |
Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy |
COMPLETED | PHASE3 |
| NCT03048578 |
Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery |
COMPLETED | PHASE4 |
| NCT03036800 |
Saxenda in Obesity Services (STRIVE Study) |
COMPLETED | PHASE4 |
